SEA4US

SEA4US

Sea4Us is a Portuguese biotechnology startup created in the sequence of the participation of the team in COHiTEC 2013. The company aims to develop novel therapeutic drugs, particularly for chronic pain, a syndrome caused by various pathologies (diabetes, cancer, arthritis, fibromyalgia, shingles, etc.) and that affects 1.5 billion people worldwide, causing a huge negative impact on society.

Sea4Us’ strategy relies on the study of some marine invertebrates such as sponges, anemones, corals or bryozoans, that, due to the fact of being fixed to the rocks and at the mercy of predators, have developed chemical defense strategies based on the secretion of toxins, many of which act as paralyzing anesthetics or powerful painkillers.

The company is settled in Sagres and is composed by three researchers, Pedro Lima, Filipe Vilas-Boas e Marisa Sousa, and one economist, Hugo Pacheco.

BIOMIMETX

BIOMIMETX

BioMimetx is a biotech startup dedicated to the research, development and marketing of innovative solutions for the control of biological proliferation.

The company is currently developing its first product, a natural-origin antifouling solution to be applied in paints for sea submerged structures. The product overcomes traditional issues such as environmental accumulation and dangerous handling of classical antifouling compounds, at a lower cost.

BioMimetx’s headquarters are in Évora and the company is composed by three researchers, Gonçalo Costa, Patrick Freire e Romana Santos, and a manager, Cristina Simões. The project that led to the company had previously participated in COHiTEC 2013 and is the result of research developed at the National Institute for Agricultural and Veterinary Research and at the University of Lisbon.

VITACONTROL

VITACONTROL

Vitacontrol, Lda. is a startup that is dedicated to the development of diagnostic kits for infectious diseases through the identification of new markers that enhance the sensitivity and specificity of the method. The immobilization of these markers in electrochemical sensors allows the company to identify small quantities of antibodies that can not be detected in diagnostic kits available on the market. The project has participated in COHitEC 2014, with the name InVita Sens.

Vitacontrol has focused its efforts on developing a diagnostic kit for leishmaniasis. This first product is distinct from the other already available in the market due to the fact that it is able to cover the asymptomatic cases, which allows a better monitoring and control of the spread of the disease.

Using a B2B business model, Vitacontrol’s mission is to develop innovative and more reliable diagnostic kits that enable saving human lives. These products are destined both to the domestic and international markets. The company’s values are based on transparent and solid relationships with all partners, customers, suppliers and employees in order to provide a high quality service and at the same time add value to society and the environment.

INNOVCAT

INNOVCAT

INNOVCAT is a technology-based startup, originated from research developed at the University of Porto, that centers its activity in the research, development and commercialization of innovative materials and solid catalysts for industrial applications in various areas, but having as main target the biofuels market.

INNOVCAT has developed a solid catalyst – X-CAT – which, along with a simple and clean technology, enables the production of biodiesel from various types of waste, significantly reducing the costs of production and operation, allowing to obtain biodiesel at a competitive price when compared with petroleum-based diesel. This solution is part of CATALVALOR project that participated in the 2013 edition of COHiTEC.

The company is composed by two researchers, Andreia Peixoto and Cristina Freire, from the Associate Laboratory for Green Chemistry – REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto.

EXOGENUS THERAPEUTICS

EXOGENUS THERAPEUTICS

Exo-T is a biotechnology company dedicated to pre-clinical and clinical development of innovative cellular based therapies applied to regenerative medicine, specifically for the skin lesions treatment. The company is presently developing its first product, Exo-Wound, for the treatment of chronic wounds.

Incubated in Biocant Park, the company was founded in 2015 by two researchers, Joana Simões Correia and Ricardo Neves and a manager, Luísa Marques. The project that led to the creation of the company (Nanoinspire) participated in COHiTEC 2014 program and is the result of the research developed in collaboration with Crioestaminal SA, Biocant and Centre for Neurosciences and Cellular Biology of Coimbra University.